More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

COVID-19 will continue to be a defining issue for the pharmaceutical industry in 2021 as new vaccines and treatments enter the market. Across the broader industry, oncology drugs continue to be a major growth driver, the industry’s late-stage...

Having received emergency use authorization from the FDA for their COVID-19 vaccine, Pfizer and BioNTech reached a significant milestone in an unprecedented effort to develop a safe and effective vaccine under accelerated timelines. What was their...

What were the key moves made by CDMOs/CMOs in 2020? Expansion activity was robust in biologic drug-substance and drug-product manufacturing, in part due to COVID-19-related projects, but other manufacturing segments had activity too. DCAT Value...

Improvements in raw material inputs are necessary in order to deploy cell & gene therapies economically and at scale. Watch an on-demand webinar featuring Avantor experts to learn about challenges associated with using non-GMP raw materials, as...

Following the adoption of the European Commission’s Pharmaceutical Strategy for Europe late last month, EU policy makers are moving forward with ways to address vulnerabilities in the global drug supply chain arising from the COVID-19 pandemic by...

COVID-19 was the most important development impacting biomanufacturing in 2020. What have been, and what will be, the adjustments required of biopharma companies, CMOs, and suppliers to fortify production capacity and supplies and respond to...

Pfizer and BioNTech have received approval for emergency use of their COVID-19 vaccine from UK regulatory authorities, making it the first COVID-19 vaccine to be approved for emergency use. What is the status of other approval requests and the next...

The COVID-19 pandemic dominated the headlines in 2020 and will again in 2021 as vaccines and treatments move through development, regulatory approval, and distribution. But what have been the other key developments thus far in 2020? How have new...

An upcoming DCAT benchmarking study is examining the lessons learned and risk-mitigation practices taken by bio/pharma companies and suppliers in the wake of the COVID-19 pandemic. What best practices can be applied to mitigate current and future...